Related Experiment Video
Updated: Oct 19, 2025
Biotinylated Cell-penetrating Peptides to Study Intracellular Protein-protein Interactions
Published on: December 20, 2017
A novel protein-drug conjugate, SSH20, demonstrates significant efficacy in caveolin-1-expressing tumors
Ryan Robb1, Jimmy Chun-Tien Kuo2, Yang Liu2
1University of North Carolina, Chapel Hill, NC, USA.
Abstract:
In recent years, human serum albumin (HSA) has been characterized as an ideal drug carrier in the cancer arena. Caveolin-1 (Cav-1) has been established as the principal structural protein of caveolae and, thus, critical for caveolae-mediated endocytosis. Cav-1 has been shown to be overexpressed in cancers of the lung and pancreas, among others. We found that Cav-1 expression plays a critical role in both HSA uptake and response to albumin-based chemotherapies. As such, developing a novel albumin-based chemotherapy that is more selective for tumors with high Cav-1 expression or high levels of caveolar-endocytosis could have significant implications in biomarker-directed therapy. Herein, we present the development of a novel and effective HSA-SN-38 conjugate (SSH20). We find that SSH20 uptake decreases significantly by immunofluorescence assays and western blotting after silencing of Cav-1 expression through RNA interference. Decreased drug sensitivity occurs in Cav-1-depleted cells using cytotoxicity assays. Importantly, we find significantly reduced sensitivity to SSH20 in Cav-1-silenced tumors compared to Cav-1-expressing tumors in vivo. Notably, we show that SSH20 is significantly more potent than irinotecan in vitro and in vivo. Together, we have developed a novel HSA-conjugated chemotherapy that is potent, effective, safe, and demonstrates improved efficacy in high Cav-1-expressing tumors.
Insights
A new human serum albumin (HSA)-SN-38 chemotherapy conjugate (SSH20) shows increased efficacy in tumors with high Caveolin-1 (Cav-1) expression. Silencing Cav-1 reduces SSH20 uptake and drug sensitivity, highlighting Cav-1 as a potential biomarker for targeted cancer therapy.
Area of Science:
- Oncology
- Drug Delivery
- Molecular Biology
Background:
- Human serum albumin (HSA) is a promising drug carrier for cancer therapy.
- Caveolin-1 (Cav-1) is crucial for caveolae-mediated endocytosis and is overexpressed in several cancers.
- Cav-1 expression influences HSA uptake and response to albumin-based chemotherapies.
Purpose of the Study:
- To develop a novel albumin-based chemotherapy selective for tumors with high Cav-1 expression.
- To evaluate the efficacy of a new HSA-SN-38 conjugate (SSH20) in relation to Cav-1 expression.
- To explore the potential of Cav-1 as a biomarker for targeted cancer therapy.
Main Methods:
- Development of a novel HSA-SN-38 conjugate (SSH20).
- Assessment of SSH20 uptake using immunofluorescence and western blotting after Cav-1 silencing via RNA interference.
- Evaluation of drug sensitivity using cytotoxicity assays in Cav-1-depleted cells and in vivo tumor models.
- Comparison of SSH20 potency against irinotecan in vitro and in vivo.
Main Results:
- SSH20 uptake and drug sensitivity were significantly reduced in Cav-1-silenced cells and tumors.
- SSH20 demonstrated significantly higher potency than irinotecan in vitro and in vivo.
- The novel HSA-conjugated chemotherapy (SSH20) showed improved efficacy in high Cav-1-expressing tumors.
Conclusions:
- Cav-1 expression is critical for the efficacy of the novel HSA-SN-38 conjugate (SSH20).
- SSH20 represents a potent and effective albumin-based chemotherapy.
- This conjugate holds promise for biomarker-directed cancer therapy, particularly in Cav-1-overexpressing tumors.
More Related Videos
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
08:29Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
